<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="12886">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02939170</url>
  </required_header>
  <id_info>
    <org_study_id>CLO870-C001</org_study_id>
    <nct_id>NCT02939170</nct_id>
  </id_info>
  <brief_title>Initial Performance of a Daily Disposable Contact Lens Featuring Molded Marks</brief_title>
  <official_title>Initial Performance of a Daily Disposable Contact Lens Featuring Molded Marks</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Alcon, a Novartis Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Alcon Research</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the impact of back surface molded marks (MM)
      applied to delefilcon A contact lenses as measured by the incidence of ocular discomfort
      device related adverse events with DAILIES TOTAL1® Multifocal contact lenses with molded
      marks (DT1 MF MM) and current DAILIES TOTAL1® Multifocal contact lenses (DT1 MF).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2016</start_date>
  <completion_date type="Actual">December 2016</completion_date>
  <primary_completion_date type="Actual">December 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single Blind (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of ocular discomfort device-related adverse events</measure>
    <time_frame>Day 1 at Hour 9</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Ocular Staining</measure>
    <time_frame>Day 1 at Hour 9</time_frame>
    <description>Assessed by the Investigator through slit-lamp examination and graded on a 5-point scale, where 0=none and 4=severe.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Limbal Hyperemia</measure>
    <time_frame>Day 1 at Hour 9</time_frame>
    <description>Assessed by the Investigator through slit-lamp examination and graded on a 5-point scale, where 0=none and 4=severe.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">87</enrollment>
  <condition>Refractive Error</condition>
  <arm_group>
    <arm_group_label>DT1 MF MM</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Delefilcon A multifocal contact lenses with molded marks on back surface worn bilaterally (in both eyes) for 9 hours</description>
  </arm_group>
  <arm_group>
    <arm_group_label>DT1 MF</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Delefilcon A multifocal contact lenses worn bilaterally for 9 hours</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Delefilcon A Multifocal Contact Lenses with Molded Mark</intervention_name>
    <arm_group_label>DT1 MF MM</arm_group_label>
    <other_name>DAILIES TOTAL1® Multifocal (DT1 MF MM)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Delefilcon A Multifocal Contact Lenses</intervention_name>
    <arm_group_label>DT1 MF</arm_group_label>
    <other_name>DAILIES TOTAL1® Multifocal (DT1 MF)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Must sign an Informed Consent document;

          -  Current wearer of commercial DAILIES TOTAL1® contact lenses;

          -  Have spectacles in current prescription available to be worn in conjunction with the
             investigational product;

          -  Manifest astigmatism less than or equal to 0.75 diopter (D) (at screening)

          -  Best corrected distance visual acuity (BCVA) greater than or equal to 20/25 in each
             eye;

          -  Other protocol-specified inclusion criteria may apply.

        Exclusion Criteria:

          -  Eye injury in either eye within 12 weeks prior to study enrollment;

          -  Any anterior segment infection, inflammation, disease, or abnormality that
             contraindicates contact lens wear;

          -  Any use of systemic or ocular medications for which contact lens wear could be
             contraindicated;

          -  History of herpetic keratitis, refractive surgery or irregular cornea;

          -  A pathologically dry eye that precludes contact lens wear;

          -  Concurrent participation in a contact lens or contact lens care product clinical
             trial within the previous 30 days;

          -  Monocular (only 1 eye with functional vision);

          -  Other protocol-specified exclusion criteria may apply.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Manager, CTM</last_name>
    <role>Study Director</role>
    <affiliation>Alcon, A Novartis Division</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Contact Alcon Call Center for Trial Locations</name>
      <address>
        <city>Fort Worth</city>
        <state>Texas</state>
        <zip>76134</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2016</verification_date>
  <lastchanged_date>December 13, 2016</lastchanged_date>
  <firstreceived_date>October 18, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Refractive Errors</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
